According to people familiar with the matter, Isomorphic Labs, an AI drug development startup spun off from Google DeepMind, a subsidiary of Alphabet, is in preliminary negotiations on a new round of financing, with a target valuation of at least 40 billion US dollars. According to one of the people familiar with the matter, the valuation of companies corresponding to this round of financing can reach up to 50 billion US dollars. People familiar with the matter said that the financing has not yet been completed, and the terms are still subject to change. Isomorphic Labs did not respond to requests for comment. Just five months ago, Isomorphic Labs closed a $2.1 billion Series B round. At the time, Demis Hassabis, CEO of the company, who is also the chairman of DeepMind, said that Alphabet provided a “large portion” of the funding for this round of financing, but declined to disclose Alphabet's shareholding ratio and the company's valuation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.